Cepharanthine is a Potent Reversal Agent for MRP7(ABCC10)-mediated Multidrug Resistance.

Ying Zhou,Elizabeth Hopper-Borge,Tong Shen,Xiao-Cong Huang,Zhi Shi,Ye-Hong Kuang,Tatsuhiko Furukawa,Shin-ichi Akiyama,Xing-Xiang Peng,Charles R. Ashby,Xiang Chen,Gary D. Kruh,Zhe-Sheng Chen
DOI: https://doi.org/10.1016/j.bcp.2008.12.005
IF: 6.1
2009-01-01
Biochemical Pharmacology
Abstract:Multidrug resistance protein 7 (MRP7; ABCC10) is an ABC transporter that confers resistance to anticancer agents such as the taxanes. We previously reported that several inhibitors of P-gp and MRP1 were able to inhibit the in vitro transport of E217βG by MRP7 in membrane vesicles transport assays. However, compounds that are able to reverse MRP7-mediated cellular resistance have not been identified. In this study, we examined the effects of cepharanthine (6′,12′-dimethoxy-2,2′-dimethyl-6,7-[methylenebis(oxy)]oxyacanthan), an herbal extract isolated from Stephania cepharantha Hayata, to reverse paclitaxel resistance in MRP7-transfected HEK293 cells. Cepharanthine, at 2μM, completely reversed paclitaxel resistance in MRP7-transfected cells. In contrast, the effect of cepharanthine on the parental transfected cells was significantly less than that on the MRP7-transfected cells. In addition, cepharanthine significantly increased the accumulation of paclitaxel in MRP7-transfected cells almost to the level of control cells in the absence of cepharanthine. The efflux of paclitaxel from MRP7-transfected cells was also significantly inhibited by cepharanthine. The ability of cepharanthine to inhibit MRP7 was analyzed in membrane vesicle assays using E217βG, an established substrate of MRP7, as a probe. E217βG transport was competitively inhibited by cepharanthine with a Ki value of 4.86μM. These findings indicate that cepharanthine reverses MRP7-mediated resistance to paclitaxel in a competitive manner.
What problem does this paper attempt to address?